Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 224

1.

Rivaroxaban in Peripheral Artery Disease after Revascularization.

Bonaca MP, Bauersachs RM, Anand SS, Debus ES, Nehler MR, Patel MR, Fanelli F, Capell WH, Diao L, Jaeger N, Hess CN, Pap AF, Kittelson JM, Gudz I, Mátyás L, Krievins DK, Diaz R, Brodmann M, Muehlhofer E, Haskell LP, Berkowitz SD, Hiatt WR.

N Engl J Med. 2020 Mar 28. doi: 10.1056/NEJMoa2000052. [Epub ahead of print]

PMID:
32222135
2.

The effectiveness of filtering glycopeptide peak list files for Y ions.

Chalkley RJ, Medzihradszky KF, Darula Z, Pap A, Baker PR.

Mol Omics. 2020 Feb 17. doi: 10.1039/c9mo00178f. [Epub ahead of print]

PMID:
32065175
3.

Novel O-linked sialoglycan structures in human urinary glycoproteins.

Pap A, Tasnadi E, Medzihradszky KF, Darula Z.

Mol Omics. 2020 Feb 5. doi: 10.1039/c9mo00160c. [Epub ahead of print]

PMID:
32022078
4.

Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial.

Male C, Lensing AWA, Palumbo JS, Kumar R, Nurmeev I, Hege K, Bonnet D, Connor P, Hooimeijer HL, Torres M, Chan AKC, Kenet G, Holzhauer S, Santamaría A, Amedro P, Chalmers E, Simioni P, Bhat RV, Yee DL, Lvova O, Beyer-Westendorf J, Biss TT, Martinelli I, Saracco P, Peters M, Kállay K, Gauger CA, Massicotte MP, Young G, Pap AF, Majumder M, Smith WT, Heubach JF, Berkowitz SD, Thelen K, Kubitza D, Crowther M, Prins MH, Monagle P; EINSTEIN-Jr Phase 3 Investigators.

Lancet Haematol. 2020 Jan;7(1):e18-e27. doi: 10.1016/S2352-3026(19)30219-4. Epub 2019 Nov 5.

PMID:
31699660
5.

Safety and efficacy of the partial adenosine A1 receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced ejection fraction: a phase IIb, randomized, double-blind, placebo-controlled trial.

Voors AA, Bax JJ, Hernandez AF, Wirtz AB, Pap AF, Ferreira AC, Senni M, van der Laan M, Butler J; PANTHEON Investigators.

Eur J Heart Fail. 2019 Nov;21(11):1426-1433. doi: 10.1002/ejhf.1591. Epub 2019 Sep 16.

PMID:
31523892
6.

Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies.

Monagle P, Lensing AWA, Thelen K, Martinelli I, Male C, Santamaría A, Samochatova E, Kumar R, Holzhauer S, Saracco P, Simioni P, Robertson J, Grangl G, Halton J, Connor P, Young G, Molinari AC, Nowak-Göttl U, Kenet G, Kapsa S, Willmann S, Pap AF, Becka M, Twomey T, Beyer-Westendorf J, Prins MH, Kubitza D; EINSTEIN-Jr Phase 2 Investigators.

Lancet Haematol. 2019 Oct;6(10):e500-e509. doi: 10.1016/S2352-3026(19)30161-9. Epub 2019 Aug 13.

PMID:
31420317
7.

The BACH1-HMOX1 Regulatory Axis Is Indispensable for Proper Macrophage Subtype Specification and Skeletal Muscle Regeneration.

Patsalos A, Tzerpos P, Halasz L, Nagy G, Pap A, Giannakis N, Lyroni K, Koliaraki V, Pintye E, Dezso B, Kollias G, Spilianakis CG, Nagy L.

J Immunol. 2019 Sep 15;203(6):1532-1547. doi: 10.4049/jimmunol.1900553. Epub 2019 Aug 12.

PMID:
31405954
8.

Analysis of microRNA expression in brush cytology specimens improves the diagnosis of pancreatobiliary cancer.

Le N, Fillinger J, Szanyi S, Wichmann B, Nagy ZB, Ivády G, Burai M, Tarpay Á, Pozsár J, Pap Á, Molnár B, Csuka O, Bak M, Tulassay Z, Szmola R.

Pancreatology. 2019 Sep;19(6):873-879. doi: 10.1016/j.pan.2019.04.001. Epub 2019 Apr 2.

PMID:
31400934
9.

"Beige" Cross Talk Between the Immune System and Metabolism.

Banfai K, Ernszt D, Pap A, Bai P, Garai K, Belharazem D, Pongracz JE, Kvell K.

Front Endocrinol (Lausanne). 2019 Jun 18;10:369. doi: 10.3389/fendo.2019.00369. eCollection 2019.

10.

Effect of Neladenoson Bialanate on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial.

Shah SJ, Voors AA, McMurray JJV, Kitzman DW, Viethen T, Bomfim Wirtz A, Huang E, Pap AF, Solomon SD.

JAMA. 2019 Jun 4;321(21):2101-2112. doi: 10.1001/jama.2019.6717.

11.

Sublingual immunotherapy alters salivary IgA and systemic immune mediators in timothy allergic children.

Huoman J, Papapavlou G, Pap A, Alm J, Nilsson LJ, Jenmalm MC.

Pediatr Allergy Immunol. 2019 Aug;30(5):522-530. doi: 10.1111/pai.13047. Epub 2019 Apr 14.

PMID:
30803044
12.

Rivaroxaban versus standard anticoagulation for acute venous thromboembolism in childhood. Design of the EINSTEIN-Jr phase III study.

Lensing AWA, Male C, Young G, Kubitza D, Kenet G, Patricia Massicotte M, Chan A, Molinari AC, Nowak-Goettl U, Pap ÁF, Adalbo I, Smith WT, Mason A, Thelen K, Berkowitz SD, Crowther M, Schmidt S, Price V, Prins MH, Monagle P.

Thromb J. 2018 Dec 21;16:34. doi: 10.1186/s12959-018-0188-y. eCollection 2018.

13.

Extended Sialylated O-Glycan Repertoire of Human Urinary Glycoproteins Discovered and Characterized Using Electron-Transfer/Higher-Energy Collision Dissociation.

Darula Z, Pap Á, Medzihradszky KF.

J Proteome Res. 2019 Jan 4;18(1):280-291. doi: 10.1021/acs.jproteome.8b00587. Epub 2018 Nov 19.

PMID:
30407017
14.

Assessing the reproducibility of an O-glycopeptide enrichment method with a novel software, Pinnacle.

Pap A, Prakash A, F Medzihradszky K, Darula Z.

Electrophoresis. 2018 Dec;39(24):3142-3147. doi: 10.1002/elps.201800223. Epub 2018 Aug 30.

PMID:
30117533
15.

Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin.

Prandoni P, Lensing AWA, Prins MH, Gebel M, Pap AF, Homering M, Bauersachs R, Beyer-Westendorf J, Bounameaux H, Cohen AT, Davidson BL, van Bellen B, Verhamme P, Wells PS, Yuan Z, Levitan B, Weitz JI.

Thromb Res. 2018 Aug;168:121-129. doi: 10.1016/j.thromres.2018.06.009. Epub 2018 Jul 10.

PMID:
30064683
16.

Arginine Methyltransferase PRMT8 Provides Cellular Stress Tolerance in Aging Motoneurons.

Simandi Z, Pajer K, Karolyi K, Sieler T, Jiang LL, Kolostyak Z, Sari Z, Fekecs Z, Pap A, Patsalos A, Contreras GA, Reho B, Papp Z, Guo X, Horvath A, Kiss G, Keresztessy Z, Vámosi G, Hickman J, Xu H, Dormann D, Hortobagyi T, Antal M, Nógrádi A, Nagy L.

J Neurosci. 2018 Aug 29;38(35):7683-7700. doi: 10.1523/JNEUROSCI.3389-17.2018. Epub 2018 Jul 27.

17.

New near-infrared rhodamine dyes with large Stokes shifts for sensitive sensing of intracellular pH changes and fluctuations.

Zhang Y, Xia S, Fang M, Mazi W, Zeng Y, Johnston T, Pap A, Luck RL, Liu H.

Chem Commun (Camb). 2018 Jul 5;54(55):7625-7628. doi: 10.1039/c8cc03520b.

18.

Consumption of conjugated linoleic acid (CLA)-supplemented diet during colitis development ameliorates gut inflammation without causing steatosis in mice.

Moreira TG, Gomes-Santos AC, Horta LS, Goncalves MC, Santiago AF, Lauar JG, Dos Reis DS, Castro-Junior AB, Lemos L, Guimarães M, Aguilar EC, Pap A, Amaral JF, Alvarez-Leite JI, Cara DC, Rezende RM, Nagy L, Faria AMC, Maioli TU.

J Nutr Biochem. 2018 Jul;57:238-245. doi: 10.1016/j.jnutbio.2018.04.003. Epub 2018 Apr 27.

PMID:
29800810
19.

Status Report on the High-Throughput Characterization of Complex Intact O-Glycopeptide Mixtures.

Pap A, Klement E, Hunyadi-Gulyas E, Darula Z, Medzihradszky KF.

J Am Soc Mass Spectrom. 2018 Jun;29(6):1210-1220. doi: 10.1007/s13361-018-1945-7. Epub 2018 May 5.

PMID:
29730764
20.

Risk of recurrent venous thromboembolism according to baseline risk factor profiles.

Prins MH, Lensing AWA, Prandoni P, Wells PS, Verhamme P, Beyer-Westendorf J, Bauersachs R, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Kakkar AK, van Bellen B, Pap AF, Homering M, Tamm M, Weitz JI.

Blood Adv. 2018 Apr 10;2(7):788-796. doi: 10.1182/bloodadvances.2018017160.

21.

Liver X Receptor Nuclear Receptors Are Transcriptional Regulators of Dendritic Cell Chemotaxis.

Beceiro S, Pap A, Czimmerer Z, Sallam T, Guillén JA, Gallardo G, Hong C, A-Gonzalez N, Tabraue C, Diaz M, Lopez F, Matalonga J, Valledor AF, Dominguez P, Ardavin C, Delgado-Martin C, Partida-Sanchez S, Rodriguez-Fernandez JL, Nagy L, Tontonoz P, Castrillo A.

Mol Cell Biol. 2018 Apr 30;38(10). pii: e00534-17. doi: 10.1128/MCB.00534-17. Print 2018 May 15.

22.

PPARgamma Deficiency Counteracts Thymic Senescence.

Ernszt D, Banfai K, Kellermayer Z, Pap A, Lord JM, Pongracz JE, Kvell K.

Front Immunol. 2017 Nov 6;8:1515. doi: 10.3389/fimmu.2017.01515. eCollection 2017.

23.

Retinoid X receptor suppresses a metastasis-promoting transcriptional program in myeloid cells via a ligand-insensitive mechanism.

Kiss M, Czimmerer Z, Nagy G, Bieniasz-Krzywiec P, Ehling M, Pap A, Poliska S, Boto P, Tzerpos P, Horvath A, Kolostyak Z, Daniel B, Szatmari I, Mazzone M, Nagy L.

Proc Natl Acad Sci U S A. 2017 Oct 3;114(40):10725-10730. doi: 10.1073/pnas.1700785114. Epub 2017 Sep 18.

24.

Browning deficiency and low mobilization of fatty acids in gonadal white adipose tissue leads to decreased cold-tolerance of transglutaminase 2 knock-out mice.

Mádi A, Cuaranta-Monroy I, Lénárt K, Pap A, Mezei ZA, Kristóf E, Oláh A, Vámosi G, Bacsó Z, Bai P, Fésüs L.

Biochim Biophys Acta Mol Cell Biol Lipids. 2017 Dec;1862(12):1575-1586. doi: 10.1016/j.bbalip.2017.07.014. Epub 2017 Aug 1.

PMID:
28774822
25.

In situ macrophage phenotypic transition is affected by altered cellular composition prior to acute sterile muscle injury.

Patsalos A, Pap A, Varga T, Trencsenyi G, Contreras GA, Garai I, Papp Z, Dezso B, Pintye E, Nagy L.

J Physiol. 2017 Sep 1;595(17):5815-5842. doi: 10.1113/JP274361. Epub 2017 Aug 8.

26.

Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism.

Weitz JI, Lensing AWA, Prins MH, Bauersachs R, Beyer-Westendorf J, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Freitas MCS, Holberg G, Kakkar AK, Haskell L, van Bellen B, Pap AF, Berkowitz SD, Verhamme P, Wells PS, Prandoni P; EINSTEIN CHOICE Investigators.

N Engl J Med. 2017 Mar 30;376(13):1211-1222. doi: 10.1056/NEJMoa1700518. Epub 2017 Mar 18.

27.

Prospective, randomised trial of the time dependent antiplatelet effects of 500 mg and 250 mg acetylsalicylic acid i. v. and 300 mg p. o. in ACS (ACUTE).

Zeymer U, Hohlfeld T, Vom Dahl J, Erbel R, Münzel T, Zahn R, Roitenberg A, Breitenstein S, Pap ÁF, Trenk D.

Thromb Haemost. 2017 Feb 28;117(3):625-635. doi: 10.1160/TH16-08-0650. Epub 2017 Jan 19.

PMID:
28102427
28.

Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials.

Beyer-Westendorf J, Lensing AW, Arya R, Bounameaux H, Cohen AT, Wells PS, Middeldorp S, Verhamme P, Hughes R, Kucher N, Pap AF, Trajanovic M, Prins MH, Prandoni P, Weitz JI.

Thromb Res. 2017 Jan;149:29-37. doi: 10.1016/j.thromres.2016.11.014. Epub 2016 Nov 21.

PMID:
27886530
29.

Immunogenic Dendritic Cell Generation from Pluripotent Stem Cells by Ectopic Expression of Runx3.

Takacs E, Boto P, Simo E, Csuth TI, Toth BM, Raveh-Amit H, Pap A, Kovács EG, Kobolak J, Benkö S, Dinnyes A, Szatmari I.

J Immunol. 2017 Jan 1;198(1):239-248. Epub 2016 Nov 16.

30.

Macrophage PPARγ, a Lipid Activated Transcription Factor Controls the Growth Factor GDF3 and Skeletal Muscle Regeneration.

Varga T, Mounier R, Patsalos A, Gogolák P, Peloquin M, Horvath A, Pap A, Daniel B, Nagy G, Pintye E, Póliska S, Cuvellier S, Larbi SB, Sansbury BE, Spite M, Brown CW, Chazaud B, Nagy L.

Immunity. 2016 Nov 15;45(5):1038-1051. doi: 10.1016/j.immuni.2016.10.016. Epub 2016 Nov 8.

31.

Using "spectral families" to assess the reproducibility of glycopeptide enrichment: human serum O-glycosylation revisited.

Pap A, Medzihradszky KF, Darula Z.

Anal Bioanal Chem. 2017 Jan;409(2):539-550. doi: 10.1007/s00216-016-9960-7. Epub 2016 Oct 20.

PMID:
27766363
32.

Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. A post-hoc analysis.

Cheung YW, Middeldorp S, Prins MH, Pap AF, Lensing AW, Ten Cate-Hoek AJ, Villalta S, Milan M, Beyer-Westendorf J, Verhamme P, Bauersachs RM, Prandoni P; Einstein PTS Investigators Group.

Thromb Haemost. 2016 Sep 27;116(4):733-8. doi: 10.1160/TH16-01-0041. Epub 2016 Sep 1.

PMID:
27583311
33.

Is the Mouse a Good Model of Human PPARγ-Related Metabolic Diseases?

Pap A, Cuaranta-Monroy I, Peloquin M, Nagy L.

Int J Mol Sci. 2016 Jul 30;17(8). pii: E1236. doi: 10.3390/ijms17081236. Review.

34.

Risk of major bleeding in patients with venous thromboembolism treated with rivaroxaban or with heparin and vitamin K antagonists.

Di Nisio M, Ageno W, Rutjes AW, Pap AF, Büller HR.

Thromb Haemost. 2016 Jan;115(2):424-32. doi: 10.1160/TH15-06-0474. Epub 2015 Oct 29.

PMID:
26511068
35.

Erratum: PPARγ activation but not PPARγ haplodeficiency affects proangiogenic potential of endothelial cells and bone marrow-derived progenitors.

Kotlinowski J, Grochot-Przeczek A, Taha H, Kozakowska M, Pilecki B, Skrzypek K, Zimoch J, Bartelik A, Derlacz R, Horrevoets AJ, Pap A, Nagy L, Dulak J, Jozkowicz A.

Cardiovasc Diabetol. 2015 May 29;14:65. doi: 10.1186/s12933-015-0205-4. No abstract available.

36.

Treatment of pulmonary embolism with rivaroxaban: outcomes by simplified Pulmonary Embolism Severity Index score from a post hoc analysis of the EINSTEIN PE study.

Fermann GJ, Erkens PM, Prins MH, Wells PS, Pap ÁF, Lensing AW.

Acad Emerg Med. 2015 Mar;22(3):299-307. doi: 10.1111/acem.12615. Epub 2015 Feb 25.

37.

[The message from heroin overdoses].

Pap Á, Hegedűs K.

Orv Hetil. 2015 Mar 1;156(9):352-7. doi: 10.1556/OH.2015.30091. Review. Hungarian.

PMID:
25702255
38.

Use of prestudy heparin did not influence the efficacy and safety of rivaroxaban in patients treated for symptomatic venous thromboem-bolism in the EINSTEIN DVT and EINSTEIN PE studies.

Prandoni P, Prins MH, Cohen AT, Müller K, Pap ÁF, Tewes MC, Lensing AW.

Acad Emerg Med. 2015 Feb;22(2):142-9. doi: 10.1111/acem.12585. Epub 2015 Feb 9.

39.

[Pancreatic cancer. Evidence based management guidelines of the Hungarian Pancreatic Study Group].

Szmola R, Farkas G, Hegyi P, Czakó L, Dubravcsik Z, Hritz I, Kelemen D, Lásztity N, Morvay Z, Oláh A, Párniczky A, Rubovszky G, Sahin-Tóth M, Szentkereszti Z, Szücs Á, Takács T, Tiszlavicz L, Pap Á; Magyar Hasnyálmirigy Munkacsoport, Hungarian Pancreatic Study Group.

Orv Hetil. 2015 Feb 22;156(8):326-39. doi: 10.1556/OH.2015.30063. Review. Hungarian.

PMID:
25662149
40.

[Pediatric pancreatitis. Evidence based management guidelines of the Hungarian Pancreatic Study Group].

Párniczky A, Czakó L, Dubravcsik Z, Farkas G, Hegyi P, Hritz I, Kelemen D, Morvay Z, Oláh A, Pap Á, Sahin-Tóth M, Szabó F, Szentkereszti Z, Szmola R, Takács T, Tiszlavicz L, Veres G, Szücs Á, Lásztity N; Magyar Hasnyálmirigy Munkacsoport, Hungarian Pancreatic Study Group.

Orv Hetil. 2015 Feb 22;156(8):308-25. doi: 10.1556/OH.2015.30062. Review. Hungarian.

PMID:
25662148
41.

[Autoimmune pancreatitis. Evidence based management guidelines of the Hungarian Pancreatic Study Group].

Dubravcsik Z, Farkas G, Hegyi P, Hritz I, Kelemen D, Lásztity N, Morvay Z, Oláh A, Pap Á, Párniczky A, Sahin-Tóth M, Szentkereszti Z, Szmola R, Takács T, Tiszlavicz L, Szücs Á, Czakó L; Magyar Hasnyálmirigy Munkacsoport, Hungarian Pancreatic Study Group.

Orv Hetil. 2015 Feb 22;156(8):292-307. doi: 10.1556/OH.2015.30061. Review. Hungarian.

PMID:
25662147
42.

[Chronic pancreatitis. Evidence based management guidelines of the Hungarian Pancreatic Study Group].

Takács T, Czakó L, Dubravcsik Z, Farkas G, Hegyi P, Hritz I, Kelemen D, Lásztity N, Morvay Z, Oláh A, Pap Á, Párniczky A, Patai Á, Sahin-Tóth M, Szentkereszti Z, Szmola R, Tiszlavicz L, Szücs Á; Magyar Hasnyálmirigy Munkacsoport.

Orv Hetil. 2015 Feb 15;156(7):262-88. doi: 10.1556/OH.2015.30060. Review. Hungarian.

PMID:
25661971
43.

[Acute pancreatitis. Evidence-based practice guidelines, prepared by the Hungarian Pancreatic Study Group].

Hritz I, Czakó L, Dubravcsik Z, Farkas G, Kelemen D, Lásztity N, Morvay Z, Oláh A, Pap Á, Párniczky A, Sahin-Tóth M, Szentkereszti Z, Szmola R, Szücs Á, Takács T, Tiszlavicz L, Hegyi P; Magyar Hasnyálmirigy Munkacsoport, Hungarian Pancreatic Study Group.

Orv Hetil. 2015 Feb 15;156(7):244-61. doi: 10.1556/OH.2015.30059. Review. Hungarian.

PMID:
25661970
44.

PPARγ activation but not PPARγ haplodeficiency affects proangiogenic potential of endothelial cells and bone marrow-derived progenitors.

Kotlinowski J, Grochot-Przeczek A, Taha H, Kozakowska M, Pilecki B, Skrzypek K, Bartelik A, Derlacz R, Horrevoets AJ, Pap A, Nagy L, Dulak J, Jozkowicz A.

Cardiovasc Diabetol. 2014 Nov 1;13:150. doi: 10.1186/s12933-014-0150-7. Erratum in: Cardiovasc Diabetol. 2015;14:65.

45.

Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials.

Prins MH, Lensing AW, Brighton TA, Lyons RM, Rehm J, Trajanovic M, Davidson BL, Beyer-Westendorf J, Pap ÁF, Berkowitz SD, Cohen AT, Kovacs MJ, Wells PS, Prandoni P.

Lancet Haematol. 2014 Oct;1(1):e37-46. doi: 10.1016/S2352-3026(14)70018-3. Epub 2014 Sep 28.

PMID:
27030066
46.

Fractal kinetic behavior of plasmin on the surface of fibrin meshwork.

Varjú I, Tenekedjiev K, Keresztes Z, Pap AE, Szabó L, Thelwell C, Longstaff C, Machovich R, Kolev K.

Biochemistry. 2014 Oct 14;53(40):6348-56. doi: 10.1021/bi500661m. Epub 2014 Sep 26.

PMID:
25222106
47.

Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment.

Bauersachs RM, Lensing AW, Prins MH, Kubitza D, Pap ÁF, Decousus H, Beyer-Westendorf J, Prandoni P.

Thromb J. 2014 Nov 24;12:25. doi: 10.1186/1477-9560-12-25. eCollection 2014.

48.

Rivaroxaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies.

Wang Y, Wang C, Chen Z, Zhang J, Liu Z, Jin B, Ying K, Liu C, Shao Y, Jing Z, Meng IL, Prins MH, Pap AF, Müller K, Lensing AW; Chinese EINSTEIN Investigators.

Thromb J. 2013 Dec 16;11(1):25. doi: 10.1186/1477-9560-11-25.

49.

Alternatives for the intensive follow-up after curative resection of colorectal cancer. Potential novel biomarkers for the recommendations.

Orosz E, Ember I, Gombos K, Tóth L, Tarpay Á, Pap Á, Ottó S.

Pathol Oncol Res. 2013 Oct;19(4):619-29. doi: 10.1007/s12253-013-9672-7. Epub 2013 Jul 19. Review.

50.

RDH10, RALDH2, and CRABP2 are required components of PPARγ-directed ATRA synthesis and signaling in human dendritic cells.

Gyöngyösi A, Szatmari I, Pap A, Dezso B, Pos Z, Széles L, Varga T, Nagy L.

J Lipid Res. 2013 Sep;54(9):2458-74. doi: 10.1194/jlr.M038984. Epub 2013 Jul 6.

Supplemental Content

Support Center